多项减重药研发成果亮相ADA大会 国产药数据比肩跨国同行

第一财经
22 Jun

在美国当地时间6月20日至23日举行的美国糖尿病协会(ADA)科学年会上,来自礼来、诺和诺德等跨国厂商以及中国制药公司的多项GLP-1减重药最新临床数据公布。  北京大学人民医院纪立农教授在ADA大会上报告了最新发表在《柳叶刀·糖尿病与内分泌学》杂志上的一项由国内先为达生物研发的GLP-1受体激动剂埃诺格鲁肽(Ecnoglutide)三期临床结果,在48周的治疗过程中,患者平均减重10%至15%,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10